Skip to main content

05-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Updated KEYNOTE-426 data

Elizabeth Plimack presents the 2-year update of the KEYNOTE-426 study pitting the combination of pembrolizumab plus axitinib against sunitinib for treatment-naïve advanced renal cell carcinoma (1:45).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Read transcript

Image Credits